On October 14th, the American Society of Nephrology (ASN) released the “Kidney Week Abstracts,” including five abstracts from Keryx Biopharmaceuticals’ (NASDAQ:KERX) Aurxyia (ferric …
Keryx Biopharmaceuticals (NASDAQ:KERX) just withdrew guidance for 2016 after an interrupted drug supply for its only pipeline drug, Auryxia, a drug created to …
Keryx Biopharmaceuticals (NASDAQ:KERX) shares are tumbling nearly 12% in early trading, following an impending supply interruption for key pipeline drug, Auryxia, a drug created …
Keryx Biopharmaceuticals (NASDAQ:KERX) announced that an interruption in the supply of Auryxia® (ferric citrate) tablets is imminent due to a production-related issue converting active …
After an encouraging update from Keryx Biopharmaceuticals (NASDAQ:KERX) management about approved drug Auryxia, a phosphate binder designed to treat iron deficiency anemia (IDA) …
In a research report published Friday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX), while raising the price …
Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that Douglas Jermasek will join the …
Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, announced that Michael Heffernan and Jodie Morrison joined …
Repros Therapeutics Inc (NASDAQ:RPRX) is soaring nearly 19% this morning to $2.01 following yesterday’s positive news that provided an update on the company’s …
Healthcare analysts at sell-side firms FBR and Brean Capital were out today with some commentary on small-cap biotech companies Advaxis, Inc. (NASDAQ:ADXS) and Keryx Biopharmaceuticals (NASDAQ:KERX).
